Memo To File: FDA Managers Rebut Rogue Reviewer
This article was originally published in RPM Report
Executive Summary
Here is a May 14 memo “to the file” signed by ODE I Director Ellis Unger, Deputy Director Robert Temple and Cardio-Renal Drug Products Division Director Norman Stockbridge, responding to the “unsolicited” reviews of Avandia submitted by cardio-renal division reviewer Thomas Marciniak. It was included in the briefing documents provided to the FDA advisory committee ahead of a June 5-6 meeting.